A Study on the Effection of Potassium Citrate Extended-release Tablets on Urolithiasis Formation or Recurrence

NCT03007160 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 2001

Last updated 2018-02-01

No results posted yet for this study

Summary

Assess the efficacy and safety of potassium citrate extended-release tablets on Urolithiasis formation or recurrence.

Conditions

  • Urolithiasis

Interventions

DRUG

Potassium Citrate Extended-release Tablets

Daily 3.24g, Po ,Tid, each 1.08g/tablets

Sponsors & Collaborators

  • Dawnrays Pharmaceutical (Holdings) Limited

    lead INDUSTRY

Principal Investigators

  • Zhangqun YE, M.D. · Tongji Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2020-09-30
Completion
2020-09-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03007160 on ClinicalTrials.gov